Background
Background The use of
The use of complementary medicines in those with complementary medicines in those with mental health problems is well mental health problems is well documented.However, their effectiveness documented.However, their effectiveness is often not established and they may be is often not established and they may be less harmless than commonly assumed. less harmless than commonly assumed.
Aims Aims To review the complementary
To review the complementary medicines routinely encountered in medicines routinely encountered in psychiatric practice, their effectiveness, psychiatric practice, their effectiveness, potential adverse effects and interactions. potential adverse effects and interactions.
Method Method Electronic and manual
Electronic and manual literature search on the effectiveness and literature search on the effectiveness and safety of psychotropic complementary safety of psychotropic complementary medicines. medicines.
Results

Results Potentially useful substances
Potentially useful substances include ginkgo and hydergine as cognitive include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as enhancers, passion flower and valerian as sedatives, St John's wort and ssedatives, St John's wort and sadenosylmethionine as antidepressants, adenosylmethionine as antidepressants, and selenium and folate to complement and selenium and folate to complement antidepressants.The evidence is less antidepressants.The evidence is less conclusive for the use of omega-3 fatty conclusive for the use of omega-3 fatty acids as augmentation treatment in acids as augmentation treatment in schizophrenia, melatonin for tardive schizophrenia, melatonin for tardive dyskinesia and18-methoxycoronaridine, dyskinesia and18-methoxycoronaridine, an ibogaine derivative, for the treatment an ibogaine derivative, for the treatment of cocaine and heroin addiction. of cocaine and heroin addiction.
Conclusions Conclusions Systematic clinical trials
Systematic clinical trials are needed to test promising substances. are needed to test promising substances. Meanwhile, those wishing to take Meanwhile, those wishing to take psychotropic complementary medicines psychotropic complementary medicines require appropriate advice. require appropriate advice.
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Complementary medicines are either used Complementary medicines are either used as an alternative or in addition to convenas an alternative or in addition to conventional medicine (Zimmerman & Thomptional medicine (Zimmerman & Thompson, 2002) . Their use by those with son, 2002) . Their use by those with chronic disorders such as cancers, with chronic disorders such as cancers, with their associated physical and psychological their associated physical and psychological problems, is well documented (Eisenberg problems, is well documented (Eisenberg et al et al, 1993; Ernst & Cassileth, 1999) . In , 1993; Ernst & Cassileth, 1999) . In psychiatric patients, estimates of their use psychiatric patients, estimates of their use range from 8 to 57%, with the most frerange from 8 to 57%, with the most frequent use being in depression and anxiety. quent use being in depression and anxiety. A population-based study from the USA A population-based study from the USA found that 9% of respondents had anxiety found that 9% of respondents had anxiety attacks, 57% of whom used complemenattacks, 57% of whom used complementary medicines; 7% of respondents reported tary medicines; 7% of respondents reported severe depression, with 54% of these using severe depression, with 54% of these using complementary medicines (Kessler complementary medicines (Kessler et al et al, , 2001 ). Another survey from the USA re-2001). Another survey from the USA reported mental disorders in 14% of responported mental disorders in 14% of respondents, 21% of whom used complementary dents, 21% of whom used complementary medicines (Unutzer medicines (Unutzer et al et al, 2000) . Usage , 2000) . Usage was highest (32%) in respondents with was highest (32%) in respondents with panic disorder. In studies restricted to those panic disorder. In studies restricted to those with psychiatric disorders, usage ranged with psychiatric disorders, usage ranged from 13 to 54% (Knaudt from 13 to 54% (Knaudt et al et al, 2001; Wang , 2001; Wang et al et al, 2001; Alderman & Kiepfer, 2003; Alderman & Kiepfer, 2003; Matthews Matthews et al et al, 2003) . Complementary , 2003) . Complementary medicines are also used by those seen by medicines are also used by those seen by liaison psychiatrists and a recent study of liaison psychiatrists and a recent study of cancer patients showed that 25% took cancer patients showed that 25% took substances with psychoactive properties substances with psychoactive properties (Werneke (Werneke et al et al, 2004 (Werneke et al et al, , 2004a . ). Complementary medicines can be Complementary medicines can be grouped into herbal remedies, food supplegrouped into herbal remedies, food supplements, including vitamin preparations, and ments, including vitamin preparations, and other organic and inorganic substances, inother organic and inorganic substances, including omega-3 fatty acids. Some people cluding omega-3 fatty acids. Some people take food supplements and vitamin pretake food supplements and vitamin preparations in high doses, often outside the parations in high doses, often outside the safety margins recommended by the Food safety margins recommended by the Food Standards Agency (Food Standards Agency, Standards Agency (Food Standards Agency, 2003) . People with mental health problems 2003). People with mental health problems may take complementary medicines to treat may take complementary medicines to treat anxiety and depression or to counter sideanxiety and depression or to counter sideeffects of conventional treatments, for exeffects of conventional treatments, for example tardive dyskinesia and weight gain. ample tardive dyskinesia and weight gain. Some seek a more holistic approach to Some seek a more holistic approach to treatment, others hope that complementary treatment, others hope that complementary medicines have fewer or no side-effects, and medicines have fewer or no side-effects, and many with chronic anxiety and depression many with chronic anxiety and depression understandably feel disillusioned by the apunderstandably feel disillusioned by the apparent ineffectiveness of conventional treatparent ineffectiveness of conventional treatment. The aim of this review is to acquaint ment. The aim of this review is to acquaint psychiatrists with the complementary medpsychiatrists with the complementary medicines routinely encountered in clinical icines routinely encountered in clinical practice, to review the evidence base for practice, to review the evidence base for their purported effectiveness and to discuss their purported effectiveness and to discuss potential adverse effects and interactions. potential adverse effects and interactions.
METHOD METHOD
We searched the Medline and Cochrane We searched the Medline and Cochrane databases for evidence of the effectiveness databases for evidence of the effectiveness of complementary medicines for the treatof complementary medicines for the treatment of psychiatric conditions. We divided ment of psychiatric conditions. We divided the substances into different categories: the substances into different categories: cognitive enhancers, sedatives and anxiolycognitive enhancers, sedatives and anxiolytics, antidepressants, antipsychotics and tics, antidepressants, antipsychotics and remedies for movement disorders, and remedies for movement disorders, and anti-addictives. Economics, 2000) for further information on the identified substances. formation on the identified substances. Where available, we used reviews summarWhere available, we used reviews summarising the proposed mechanism of action and ising the proposed mechanism of action and effectiveness, since presenting all the evieffectiveness, since presenting all the evidence in detail was beyond the scope of this dence in detail was beyond the scope of this paper. Whenever possible, we gave priority paper. Whenever possible, we gave priority to meta-analyses, systematic reviews and to meta-analyses, systematic reviews and double-blind randomised controlled trials double-blind randomised controlled trials (RCTs), but we also included other evi-(RCTs), but we also included other evidence such as open trials and case reports dence such as open trials and case reports when the findings were relevant to our when the findings were relevant to our review. Where standardised comparative review. Where standardised comparative measures such as the Hamilton Rating measures such as the Hamilton Rating Scale for Depression (HRSD; Hamilton, Scale for Depression Hamilton, 1967) were available for meta-analyses, 1967) were available for meta-analyses, we reported the relevant risk ratios. Owing we reported the relevant risk ratios. Owing to the heterogeneity of the data, no attempt to the heterogeneity of the data, no attempt at meta-analysis of other trials was made. at meta-analysis of other trials was made. We included only studies applicable to genWe included only studies applicable to general adult psychiatry and psychiatry of olderal adult psychiatry and psychiatry of older adults. Other special patient groups and er adults. Other special patient groups and healthy volunteers were excluded, as were healthy volunteers were excluded, as were studies on a combination of substances studies on a combination of substances with evidence available for the single with evidence available for the single substance (Fig. 1) . substance ( Fig. 1) .
RESULTS RESULTS
Two thousand and seven studies were identiTwo thousand and seven studies were identified for the 20 remedies under review for the fied for the 20 remedies under review for the five categories of mental health problems. five categories of mental health problems. The literature ranged from case reports and The literature ranged from case reports and narrative reviews to systematic reviews innarrative reviews to systematic reviews including meta-analyses. For four categories, cluding meta-analyses. For four categories, the evidence with regard to efficacy could the evidence with regard to efficacy could be limited to RCTs, systematic reviews and be limited to RCTs, systematic reviews and meta-analyses. For anti-addictive substances meta-analyses. For anti-addictive substances we also considered open trials, since there we also considered open trials, since there was very little evidence available (Fig. 1) . was very little evidence available (Fig. 1) .
Cognitive enhancers Cognitive enhancers
Cognitive enhancers are either used in the Cognitive enhancers are either used in the treatment of dementia to enhance mental treatment of dementia to enhance mental performance or to prevent cognitive decline performance or to prevent cognitive decline in healthy people. This can be achieved by in healthy people. This can be achieved by increasing choline availability in the brain, increasing choline availability in the brain, e.g. by inhibiting acetylcholinesterase. e.g. by inhibiting acetylcholinesterase. Alternative non-cholinergic neuroprotecAlternative non-cholinergic neuroprotective strategies have been postulated; these tive strategies have been postulated; these include antioxidants scavenging free radiinclude antioxidants scavenging free radicals, thereby reducing neurotoxicity, and cals, thereby reducing neurotoxicity, and anticoagulants increasing cerebral blood anticoagulants increasing cerebral blood flow (Spinella, 2001) . Suggested herbal flow (Spinella, 2001) . Suggested herbal cognitive enhancers include ginkgo, gincognitive enhancers include ginkgo, ginseng, hydergine, which is an ergot ( seng, hydergine, which is an ergot (Clavi-Claviceps purpurea ceps purpurea) derivative, and solanceous ) derivative, and solanceous plants, including potatoes, tomatoes and plants, including potatoes, tomatoes and aubergines (Table 1) . aubergines (Table 1) .
Although in some individuals with Although in some individuals with Alzheimer's disease ginkgo biloba has been Alzheimer's disease ginkgo biloba has been reported to improve cognitive performance reported to improve cognitive performance (Birks (Birks et al et al, 2002; Kanowski & Hoerr, , 2002; Kanowski & Hoerr, 2003) , another trial did not show any ben-2003), another trial did not show any benefit in elderly people with Alzheimer's disefit in elderly people with Alzheimer's disease of vascular type or age-associated ease of vascular type or age-associated cognitive impairment (van Dongen cognitive impairment (van Dongen et al et al, , 2003) . Whether the effect in those with Alz-2003) . Whether the effect in those with Alzheimer's disease is equivalent to that of synheimer's disease is equivalent to that of synthetic cholinesterase inhibitors is debatable thetic cholinesterase inhibitors is debatable (Itil (Itil et al et al, 1998; Wettstein, 2000; Schreiter-, 1998; Wettstein, 2000; SchreiterGasser & Gasser, 2001) . Hydergine Gasser & Gasser, 2001) . Hydergine was reported to lead to significant improvewas reported to lead to significant improvement of cognitive impairment in dementia, ment of cognitive impairment in dementia, but most studies were performed before but most studies were performed before standardised dementia criteria were agreed standardised dementia criteria were agreed (Olin (Olin et al et al, 2001) . The results for panax , 2001). The results for panax ginseng and vitamin E were inconclusive ginseng and vitamin E were inconclusive (Sano (Sano et al et al, 1997; Vogeler , 1997; Vogeler et al et al, 1999) . , 1999). Solanaceous plants may exercise strong Solanaceous plants may exercise strong cholinergic effects by inhibiting not only cholinergic effects by inhibiting not only acetyl-but also butyrylcholinesterase. acetyl-but also butyrylcholinesterase. However, no clinical studies have been conHowever, no clinical studies have been conducted to determine their effects on cogniducted to determine their effects on cognition. They may augment cocaine toxicity tion. They may augment cocaine toxicity via the same mechanism (Krasowski via the same mechanism (Krasowski et al et al, , 1997) . 1997).
Anxiolytics and sedatives Anxiolytics and sedatives
Anxiolytics and sedatives essentially have Anxiolytics and sedatives essentially have the same underlying mechanisms of action. the same underlying mechanisms of action. The stronger the agent the greater the sedaThe stronger the agent the greater the sedative effect, leading to coma in extreme tive effect, leading to coma in extreme cases. Four mechanisms of action have been cases. Four mechanisms of action have been implicated (Spinella, 2001) : (a) binding to implicated (Spinella, 2001) : (a) binding to gamma-aminobutyric acid (GABA) recepgamma-aminobutyric acid (GABA) receptors leading to hyperpolarisation of the cell tors leading to hyperpolarisation of the cell membrane through increased influx of membrane through increased influx of chlorine anions; (b) inhibition of excitatory chlorine anions; (b) inhibition of excitatory amino acids, thereby also impairing the amino acids, thereby also impairing the ability to form new memories; (c) sodium ability to form new memories; (c) sodium channel blockade, decreasing depolarisachannel blockade, decreasing depolarisation of the cell membrane; and (d) calcium tion of the cell membrane; and (d) calcium channel blockade, decreasing the release channel blockade, decreasing the release of neurotransmitters into the synaptic of neurotransmitters into the synaptic cleft. Most complementary medicines cleft. Most complementary medicines prescribed for anxiolysis/sedation (e.g. kava prescribed for anxiolysis/sedation (e.g. kava kava, valerian, passion flower and kava, valerian, passion flower and chamomile) are GABAergic, though for chamomile) are GABAergic, though for some such as hops the mechanism of action some such as hops the mechanism of action remains unknown. As expected, all remremains unknown. As expected, all remedies can lead to drowsiness when taken edies can lead to drowsiness when taken in high doses and can potentiate the effect in high doses and can potentiate the effect of synthetic sedatives (Table 2) . of synthetic sedatives (Table 2) .
The most researched substance is kava The most researched substance is kava kava ( kava (Piper methysticum Piper methysticum), which originated ), which originated from Polynesia and was traditionally used from Polynesia and was traditionally used for religious rituals (Chevallier, 1996) . for religious rituals (Chevallier, 1996 ) is a sedative believed to have been known to Galen and Dioscorides, have been known to Galen and Dioscorides, which has maintained its im which has maintained its importance portance throughout the centuries (Spinella, throughout the centuries (Spinella, 2001) .
2001). In 1845, Coffin described it as 'an excellent In 1845, Coffin described it as 'an excellent sedative . . . predisposing the mind to quietsedative . . . predisposing the mind to quietness and the body to sleep'. Valerian may ness and the body to sleep'. Valerian may have comparable efficacy to oxazepam have comparable efficacy to oxazepam (Dorn, 2000; Ziegler (Dorn, 2000; Ziegler et al et al, 2002) . However, , 2002 ). However, a systematic review on the effectiveness of a systematic review on the effectiveness of valerian in insomnia produced inconclusive valerian in insomnia produced inconclusive results (Stevinson & Ernst, 2000) . results (Stevinson & Ernst, 2000) .
Passion flower ( Passion flower (Passiflora incarnata Passiflora incarnata) ) contains chrysin, a partial agonist to benzocontains chrysin, a partial agonist to benzodiazepine receptors. One study comparing diazepine receptors. One study comparing passion flower with oxazepam found both passion flower with oxazepam found both to be equally effective (Akhondzadeh to be equally effective (Akhondzadeh et et al al, 2001 , 2001a a); more trials are needed to ); more trials are needed to confirm the effect. No data are available confirm the effect. No data are available on chamomile and hops. Chamomile on chamomile and hops. Chamomile ( (Chamaemelum nobile Chamaemelum nobile or or Matricaria Matricaria recutita recutita) contains apigenin which binds to ) contains apigenin which binds to benzodiazepine receptors (Viola benzodiazepine receptors (Viola et al et al, , 1995) . The mechanism of action for hops 1995). The mechanism of action for hops 11 0 11 0 (Benton, 2002) , and it nerve cell damage (Benton, 2002), and it is also known to facilitate conversion from is also known to facilitate conversion from thyroxine (T4) to thyronine (T3); T3 substithyroxine (T4) to thyronine (T3); T3 substitution is one possible means of augmentatution is one possible means of augmentation of antidepressants in conventional tion of antidepressants in conventional psychiatry. There are no clinical studies psychiatry. There are no clinical studies but low selenium levels have been assobut low selenium levels have been associated with depression, anxiety and hosticiated with depression, anxiety and hostility (Hawkes & Hornbostel, 1996) , and lity (Hawkes & Hornbostel, 1996) , and high dietary intake or supplementation high dietary intake or supplementation has been associated with mood improvehas been associated with mood improvement. The apparent therapeutic effect may ment. The apparent therapeutic effect may be dose-dependent (Benton & Cook, 1991; be dose-dependent (Benton & Cook, 1991; Benton, 2002 , 1998) . Thus, the use of extracts with 1998). Thus, the use of extracts with maximum hyperforin content should be maximum hyperforin content should be examined more systematically (Werneke examined more systematically (Werneke et al et al, 2004 (Werneke et al et al, , 2004b . ). Folate and S-adenosylmethionine are in Folate and S-adenosylmethionine are in the same biochemical pathway, with folate the same biochemical pathway, with folate being required to synthesise methionine, the being required to synthesise methionine, the direct precursor of S-adenosylmethionine, direct precursor of S-adenosylmethionine, from homocysteine. S-adenosylmethionine from homocysteine. S-adenosylmethionine facilitates many methylation reactions facilitates many methylation reactions required for the synthesis of many neurorequired for the synthesis of many neurotransmitters (Bottiglieri transmitters (Bottiglieri et al et al, 2000; Morris , 2000; Morris et al et al, 2003) . Thus, those with high levels , 2003). Thus, those with high levels of homocysteine may be more likely to of homocysteine may be more likely to become depressed, or possibly less likely become depressed, or possibly less likely to respond to antidepressant treatment. to respond to antidepressant treatment. Interestingly, hypothyroidism can lead to Interestingly, hypothyroidism can lead to an increase in homocysteine levels (Roberts an increase in homocysteine levels (Roberts & Ladenson, 2004 ) and this may contri-& Ladenson, 2004 ) and this may contribute to the associated depression. In clinical bute to the associated depression. In clinical studies, folate has been reported to be effecstudies, folate has been reported to be effective only when added to antidepressant tive only when added to antidepressant therapy (Taylor therapy (Taylor et al et al, 2004) . , 2004). Parenteral S-adenosylmethionine has Parenteral S-adenosylmethionine has been reported to be superior to placebo been reported to be superior to placebo (Bressa, 1994) , and equivalence to imipra- (Bressa, 1994) , and equivalence to imipramine has been demonstrated in two RCTs mine has been demonstrated in two RCTs Table 4 ). (Bowden, 2001 ; Table 4 ).
Antipsychotics, augmentation Antipsychotics, augmentation and treatment of tardive dyskinesia and treatment of tardive dyskinesia
Only two complementary medicines have Only two complementary medicines have been suggested for the treatment of been suggested for the treatment of psychosis. Rauwolfia ( psychosis. Rauwolfia (Rauwolfia serpentina Rauwolfia serpentina) ) extracts were traditionally used before extracts were traditionally used before synthetic antipsychotics became widely synthetic antipsychotics became widely available, several alkaloid derivatives, inavailable, several alkaloid derivatives, including reserpine, being introduced in the cluding reserpine, being introduced in the 1950s (Malamud 1950s (Malamud et al et al, 1957 . Rauwolfia , 1957) . Rauwolfia originates from India and was mentioned originates from India and was mentioned in Ayurvedic medicine around 700 in Ayurvedic medicine around 700 BC BC (Che-(Chevallier, 1996) . It blocks vesicular storage of vallier, 1996). It blocks vesicular storage of monoamines, allowing them to be more monoamines, allowing them to be more easily degraded by monoamine oxidases in easily degraded by monoamine oxidases in the cytoplasm. As a consequence, the the cytoplasm. As a consequence, the amount of neurotransmitter available on amount of neurotransmitter available on depolarisation of the cell membrane is redepolarisation of the cell membrane is reduced (Spinella, 2001) , which may lead to duced (Spinella, 2001) , which may lead to a reduction in dopamine and the resolution a reduction in dopamine and the resolution of psychotic symptoms. However, serotonin of psychotic symptoms. However, serotonin and noradrenaline will also be less availand noradrenaline will also be less available, which explains why reserpine readily able, which explains why reserpine readily precipitates depression. An alternative precipitates depression. An alternative strategy is the augmentation of antistrategy is the augmentation of antipsychotic treatment with omega-3 fatty psychotic treatment with omega-3 fatty acids, but the results of clinical trials remain acids, but the results of clinical trials remain inconclusive (Joy inconclusive (Joy et al et al, 2003 ; Table 5 ). , 2003; Table 5 ). Attempts have been made to treat tardAttempts have been made to treat tardive dyskinesia with vitamin E. This treative dyskinesia with vitamin E. This treatment strategy relies on the assumption ment strategy relies on the assumption that tardive dyskinesia not only results that tardive dyskinesia not only results from dopamine receptor supersensitivity from dopamine receptor supersensitivity but is also related to the oxidative tissue but is also related to the oxidative tissue damage of antipsychotic drugs (Shamir damage of antipsychotic drugs (Shamir et et al al, 2001; Lohr , 2001; Lohr et al et al, 2003) . Meta-analysis , 2003) . Meta-analysis of ten small trials has indicated that vitamin of ten small trials has indicated that vitamin E protects against deterioration of tardive E protects against deterioration of tardive dyskinesia (Soares & McGrath, 2001 ); dyskinesia (Soares & McGrath, 2001 ); one recent trial has reported improvement one recent trial has reported improvement (Zhang (Zhang et al et al, 2004) . A far more powerful , 2004). A far more powerful antioxidant than vitamin E is melatonin, antioxidant than vitamin E is melatonin, which attenuates the dopaminergic activity which attenuates the dopaminergic activity in the striatum as well as the release of in the striatum as well as the release of dopamine from the hypothalamus (Shamir dopamine from the hypothalamus (Shamir et al et al, 2001; Lohr , 2001; Lohr et al et al, 2003) . However, , 2003) . However, as with omega-3 fatty acids, clinical trials as with omega-3 fatty acids, clinical trials have been inconclusive (Shamir have been inconclusive (Shamir et al et al, , 2000 (Shamir et al et al, , , 2001 , and larger trials are required 2000, 2001) , and larger trials are required to test its therapeutic effectiveness (Table 5) . to test its therapeutic effectiveness (Table 5) .
Anti-addictives Anti-addictives
Although there are many addictive plants, Although there are many addictive plants, few have been identified as having the few have been identified as having the potential to counter addiction (Table 6 ). potential to counter addiction (Table 6 ). Such may be ibogaine, which is derived Such may be ibogaine, which is derived from the West African shrub from the West African shrub Tabernanthe Tabernanthe iboga iboga. It has hallucinogenic properties and . It has hallucinogenic properties and is traditionally used in religious ceremonies is traditionally used in religious ceremonies and initiation rites, but has also been and initiation rites, but has also been claimed to counter nicotine, cocaine and claimed to counter nicotine, cocaine and opiate addiction, via blockade of dopamine opiate addiction, via blockade of dopamine release in the nucleus accumbens (and the release in the nucleus accumbens (and the dopamine response in general) in chronic dopamine response in general) in chronic Table 3 ) inhibitor (see Table 3 ) inhibitor (see Table 3 inhibitor (see Table 3 ) inhibitor (see Table 3 Omega-3 fatty Omega-3 fatty acids acids See Table 4 See Table 4 Meta-analysis of five small studies inconcluMeta-analysis of five small studies inconclusive; the use of omega-3 fatty acids remains sive; the use of omega-3 fatty acids remains experimental until larger trials are conducted experimental until larger trials are conducted See Table 4 See Table 4 See Table 4 See Table 4 Melatonin Melatonin Antioxidant, also attenuates dopaminergic Antioxidant, also attenuates dopaminergic activity in the striatum and dopamine activity in the striatum and dopamine release from the hypothalamus (Lohr release from the hypothalamus (Lohr See Table 2 See Table 2 See Table 2 See Table 2 Vitamin E Vitamin E 
See Table 1 See Table 1 See Table 1 See Table 1 RCTs, randomised controlled trials; NMCD, Natural Medicines Comprehensive Database. RCTs, randomised controlled trials; NMCD, Natural Medicines Comprehensive Database. Table 2 See Table 2 See Table 2 See Table 2 Passion use of anxiolytic effect, see Table 2 use of anxiolytic effect, see Table 2 Opiates: effective as adjuvant therapy See Table 2 See Table 2 See Table 2 See Table 2 St John's wort for alcohol St John's wort for alcohol addiction addiction Not fully understood, and possibly related Not fully understood, and possibly related to reducing serotonin, dopamine, to reducing serotonin, dopamine, noradrenaline and GABA reuptake noradrenaline and GABA reuptake Table 3 See Table 3 See Table 3 See Table 3 Kudzu for alcohol Kudzu for alcohol addiction addiction (Staley et al et al, 1996) , but its therapeutic , 1996), but its therapeutic value is limited as it is highly neurotoxic value is limited as it is highly neurotoxic and can cause irreversible cerebellar and can cause irreversible cerebellar damage (Maisonneuve & Glick, 2003) ; as damage (Maisonneuve & Glick, 2003) ; as a result, further clinical studies have been a result, further clinical studies have been abandoned. A synthetic derivative 18-abandoned. A synthetic derivative 18-methoxycoronaridine has similar reported methoxycoronaridine has similar reported effects but no cerebellar toxicity or specific effects but no cerebellar toxicity or specific effects on the serotonin transporter effects on the serotonin transporter (Maisonneuve & Glick, 2003) . To date (Maisonneuve & Glick, 2003) . To date 18-methoxycoronaridine has only been 18-methoxycoronaridine has only been tested in animal experiments where it has tested in animal experiments where it has been shown to reduce cocaine, morphine been shown to reduce cocaine, morphine and alcohol intake in rats (Rezvani and alcohol intake in rats (Rezvani et al et al, , 1997; Glick 1997; Glick et al et al, 2000) . , 2000). Passion flower has also been used to Passion flower has also been used to ameliorate the effects of opiate, cannabis, ameliorate the effects of opiate, cannabis, benzodiazepine and nicotine addiction, 1999; Rezvani , 1999; Rezvani et al et al, 1999; , 1999; Overstreet Overstreet et al et al, 2003 , 2003b , but effectiveness ), but effectiveness has not been established. Kudzu, Japanese has not been established. Kudzu, Japanese arrowroot ( arrowroot (Pueraria lobata Pueraria lobata), has tradition-), has traditionally been used for the treatment of alcoholic ally been used for the treatment of alcoholic hangover. The active ingredient, purerarin, hangover. The active ingredient, purerarin, counteracts the anxiogenic effects assocounteracts the anxiogenic effects associated with alcohol withdrawal (Overstreet ciated with alcohol withdrawal (Overstreet et al et al, 2003 , 2003a a). Kudzu also contains two po-). Kudzu also contains two potent, reversible inhibitors of human alcohol tent, reversible inhibitors of human alcohol dehydrogenase isozymes (Keung, 1993) , dehydrogenase isozymes (Keung, 1993) , but an effect has only been demonstrated but an effect has only been demonstrated in vitro in vitro (Lin & Li, 1998) . One small trial (Lin & Li, 1998) . One small trial among those with chronic alcohol misuse among those with chronic alcohol misuse has not shown any difference from placebo has not shown any difference from placebo (Shebek & Rindone, 2000) . Further trials (Shebek & Rindone, 2000) . Further trials are required to test its genuine therapeutic are required to test its genuine therapeutic potential, perhaps using more standardised potential, perhaps using more standardised formulations of the active ingredient. formulations of the active ingredient.
DISCUSSION DISCUSSION
Our review demonstrates that the evidence Our review demonstrates that the evidence base for the use of psychotropic complebase for the use of psychotropic complementary medicines is extremely limited. mentary medicines is extremely limited. The best evidence is available for St The best evidence is available for St John's wort and kava kava, both of John's wort and kava kava, both of which are used extensively in various which are used extensively in various cultures. However, trials of St John's cultures. However, trials of St John's wort need improved definition of incluwort need improved definition of inclusion criteria (Werneke sion criteria (Werneke et al et al, 2004 (Werneke et al et al, , 2004b , ), and kava kava has been withdrawn due and kava kava has been withdrawn due to concerns about hepatotoxicity. Further to concerns about hepatotoxicity. Further RCTs are required to assess other RCTs are required to assess other promising agents such as selenium and promising agents such as selenium and S-adenosylmethionine for the treatment S-adenosylmethionine for the treatment of depression, ideally in individuals of depression, ideally in individuals showing the corresponding deficiencies showing the corresponding deficiencies at baseline. This may lead to new theraat baseline. This may lead to new therapeutic approaches for treatment-resistant peutic approaches for treatment-resistant depression. Valerian and passion flower depression. Valerian and passion flower should be tested as anxiolytics and sedashould be tested as anxiolytics and sedatives; their potential value in the treattives; their potential value in the treatment of addiction also requires further ment of addiction also requires further clarification. The role of omega-3 fatty clarification. The role of omega-3 fatty acids as an adjunct to antipsychotics acids as an adjunct to antipsychotics and melatonin as a treatment or prophyand melatonin as a treatment or prophylactic agent for tardive dyskinesia remain lactic agent for tardive dyskinesia remain ambiguous, both requiring trials with ambiguous, both requiring trials with sound methodology. sound methodology.
We have outlined only a limited range We have outlined only a limited range of complementary medicines used for the of complementary medicines used for the treatment of common psychiatric problems. treatment of common psychiatric problems. Clearly there are many more remedies that Clearly there are many more remedies that may be taken to improve general health or may be taken to improve general health or to counter the side-effects of conventional to counter the side-effects of conventional treatments. Clinicians need to be aware of treatments. Clinicians need to be aware of and enquire about such forms of selfand enquire about such forms of selfmedication, since all remedies may interact medication, since all remedies may interact with prescribed medication or have with prescribed medication or have associated side-effects in their own associated side-effects in their own right. For instance, patients may take right. For instance, patients may take phyto-oestrogens, such as black colosh phyto-oestrogens, such as black colosh ( (Actaea racemosa Actaea racemosa), wild yam ( ), wild yam (Dioscorea Dioscorea composita composita) or dong quai ( ) or dong quai (Angelica sinensis Angelica sinensis) ) to counter sexual side-effects, and this to counter sexual side-effects, and this might pose a problem in patients with might pose a problem in patients with oestrogen receptor-positive breast cancer oestrogen receptor-positive breast cancer (Werneke (Werneke et al et al, 2004 (Werneke et al et al, , 2004a . For the same ). For the same reason, patients may also try evening primreason, patients may also try evening primrose oil ( rose oil (Oenothera biennis Oenothera biennis), which could ), which could decrease the effect of sodium valproate decrease the effect of sodium valproate (Miller, 1989) . Kelp ( (Miller, 1989 Given the complex pattern of potential Given the complex pattern of potential interactions, clinicians should not be afraid interactions, clinicians should not be afraid to discuss complementary medicines with to discuss complementary medicines with their patients. Although some patients their patients. Although some patients may choose to use complementary medimay choose to use complementary medicines as alternatives to conventional treatcines as alternatives to conventional treatment, many may decide to use them in ment, many may decide to use them in addition to prescribed medications. Comaddition to prescribed medications. Complementary medicines have -rightly or plementary medicines have -rightly or wrongly -a very positive 'natural' reputawrongly -a very positive 'natural' reputation among significant sections of the popution among significant sections of the population, and therefore can be popular with lation, and therefore can be popular with those from a wide variety of cultural those from a wide variety of cultural backgrounds. This may lead to higher backgrounds. This may lead to higher acceptance and adherence compared with acceptance and adherence compared with conventional drugs, making it important conventional drugs, making it important to be 'willing and prepared to work in partto be 'willing and prepared to work in partnership with patients' beliefs and prefernership with patients' beliefs and preferences -provided their actions are safe' ences -provided their actions are safe' (Brugha (Brugha et al et al, 2004) . Also, we do not know , 2004). Also, we do not know whether the agreed use of complementary whether the agreed use of complementary medicines could in itself improve insight medicines could in itself improve insight and subsequently lead to greater adherence and subsequently lead to greater adherence to conventional treatment regimens. This to conventional treatment regimens. This emphasises the importance of further reemphasises the importance of further research on complementary medicines focusing search on complementary medicines focusing on promising agents such as passion flower, on promising agents such as passion flower, valerian and S-adenosylmethionine, which valerian and S-adenosylmethionine, which appear to be obvious candidates for further appear to be obvious candidates for further RCTs. In addition, it might be important to RCTs. In addition, it might be important to consider patients' attitudes and preferences consider patients' attitudes and preferences in future studies, possibly targeting those in future studies, possibly targeting those demanding complementary medicines. demanding complementary medicines.
Finally, clinicians need to be aware of Finally, clinicians need to be aware of side-effects associated with complementary side-effects associated with complementary medicines and any interactions with other medicines and any interactions with other treatments. They should be able to identify treatments. They should be able to identify hazards, advising patients accordingly and hazards, advising patients accordingly and avoiding uncritical encouragement of poavoiding uncritical encouragement of potentially harmful use. Ignorance in this tentially harmful use. Ignorance in this area, given the independent usage of comarea, given the independent usage of complementary medicines, may lead to criticism plementary medicines, may lead to criticism and possibly litigation (Cohen & Eisenberg, and possibly litigation (Cohen & Eisenberg, 2002) . Equally, patients should be encour-2002). Equally, patients should be encouraged to disclose information about aged to disclose information about complementary medicines to healthcare complementary medicines to healthcare professionals. These discussions need to be professionals. These discussions need to be conducted sensitively in order to avoid alieconducted sensitively in order to avoid alienating patients who may feel that they have nating patients who may feel that they have not been taken seriously or have been critinot been taken seriously or have been criticised for using complementary medicines. cised for using complementary medicines. Such discussions can be complex and may Such discussions can be complex and may demand more time than is available in demand more time than is available in routine clinics. Service models need to be routine clinics. Service models need to be designed to meet this challenge, with condesigned to meet this challenge, with consideration being given to specialist clinics sideration being given to specialist clinics providing regular updated advice to both providing regular updated advice to both clinicians and patients. clinicians and patients.
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